Have a feature idea you'd love to see implemented?
Let us know!
PCVX Vaxcyte Inc
Price (delayed)
$111.87
Market cap
$12.49B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.68
Enterprise value
$11.99B
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious
Highlights
Vaxcyte's equity has increased by 39% YoY
The debt has surged by 68% year-on-year but it has declined by 7% since the previous quarter
PCVX's quick ratio is down by 18% year-on-year but it is up by 2.7% since the previous quarter
The net income has plunged by 88% YoY and by 14% from the previous quarter
The EPS has decreased by 40% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of PCVX
Market
Valuations
Earnings
Shares outstanding
111.61M
Market cap
$12.49B
Enterprise value
$11.99B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.13
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$497.19M
EBITDA
-$485.19M
Free cash flow
-$582.34M
Per share
Balance sheet
Liquidity
EPS
-$4.68
Free cash flow per share
-$4.97
Book value per share
$18.26
Revenue per share
$0
TBVPS
$17.8
Total assets
$2.09B
Total liabilities
$101.14M
Debt
$25.58M
Equity
$1.99B
Working capital
$1.4B
Debt to equity
0.01
Current ratio
17.88
Quick ratio
17.53
Net debt/EBITDA
1.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-28.1%
Return on equity
-30.1%
Return on invested capital
-42.3%
Return on capital employed
-24.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCVX stock price
How has the Vaxcyte stock price performed over time
Intraday
0.11%
1 week
-2.08%
1 month
-2.96%
1 year
127.66%
YTD
78.14%
QTD
-2.1%
Financial performance
How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$577.16M
Net income
-$497.19M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has shrunk by 90% YoY and by 13% QoQ
The net income has plunged by 88% YoY and by 14% from the previous quarter
Growth
What is Vaxcyte's growth rate over time
Valuation
What is Vaxcyte stock price valuation
P/E
N/A
P/B
6.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 40% YoY and by 9% from the previous quarter
The P/B is 53% higher than the 5-year quarterly average of 4.0 and 53% higher than the last 4 quarters average of 4.0
Vaxcyte's equity has increased by 39% YoY
Efficiency
How efficient is Vaxcyte business performance
PCVX's ROIC is up by 29% year-on-year
Vaxcyte's return on equity has decreased by 4.9% YoY and by 4.5% QoQ
PCVX's ROA is down by 4.5% QoQ and by 4.1% YoY
Dividends
What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCVX.
Financial health
How did Vaxcyte financials performed over time
The total liabilities has increased by 46% year-on-year but it has declined by 6% since the previous quarter
The company's total assets rose by 39% YoY
The debt is 99% smaller than the equity
The debt has surged by 68% year-on-year but it has declined by 7% since the previous quarter
Vaxcyte's equity has increased by 39% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.